Abstract 5571: Disruption of cell-intrinsic checkpoint regulator CTLA-4 in CD19 directed CAR T cells provides clinical efficacy in CLL patients
Sangya Agarwal(Amgen (United States)), Carl H. June(University of Pennsylvania), Gabriela Plesa(University of Pennsylvania), Joseph A. Fraietta(University of Pennsylvania), Pranali Ravikumar(Parker Institute for Cancer Immunotherapy), Angela Aznar Gomez(University of Pennsylvania), Megan M. Davis(California University of Pennsylvania), David L. Porter(Chapman University), Mercy Gohil(University of Pennsylvania), Regina M. Young(University of Pennsylvania), Weimin Kong(Bengbu Medical College), Tong Da(University of Pennsylvania), Shunichiro Kuramitsu(University of Pennsylvania)
Cited by 2
Related Papers
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940
Targeting cardiac fibrosis with engineered T cells
|Nature|2019|799
An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer
|American Journal of Hematology|2019|608
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
|JCI Insight|2018|573